# PRODUCT INFORMATION



# UR-144 N-(5-hydroxypentyl) metabolite-d<sub>5</sub>

Item No. 14375

CAS Registry No.: 2748525-42-8

[1-(5-hydroxypentyl)-1H-indol-3-yl-2,4,5,6,7-d<sub>5</sub>] Formal Name:

(2,2,3,3-tetramethylcyclopropyl)-methanone

Synonym: XLR11 N-(5-hydroxypentyl) metabolite-d<sub>5</sub>

MF:  $C_{21}H_{24}D_5NO_2$ 

332.5 FW:

**Chemical Purity:** ≥98% (UR-144 N-(5-hydroxypentyl) metabolite)


Deuterium

Incorporation:  $\geq$ 99% deuterated forms (d<sub>1</sub>-d<sub>5</sub>);  $\leq$ 1% d<sub>0</sub>

UV/Vis.:  $\lambda_{max}$ : 219, 255, 298 nm A solution in acetonitrile Supplied as:

Storage: -20°C ≥4 yeas Stability:

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



## Description

UR-144 N-(5-hydroxypentyl) metabolite-d<sub>5</sub> (Item No. 14375) is intended for use as an internal standard for the quantification of UR-144 N-(5-hydroxypentyl) metabolite by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

UR-144 is a potent synthetic cannabinoid (CB) that preferentially binds the peripheral CB2 receptor  $(K_i = 1.8 \text{ nM})$  over the central CB<sub>1</sub> receptor  $(K_i = 150 \text{ nM})$ . UR-144 N-(5-hydroxypentyl) metabolite is an expected phase I metabolite of UR-144, based on the metabolism of similar cannabimimetics.<sup>2,3</sup> This metabolite should be detectable in either serum or urine. The physiological and toxicological properties of this compound have not been tested. This product is intended for forensic and research applications.

# References

- 1. Frost, J.M., Dart, M.J., Tietje, K.R., et al. Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB<sub>2</sub> cannabinoid receptor activity. J. Med. Chem. 53(1), 295-315 (2010).
- Wintermeyer, A., Möller, I., Thevis, M., et al. In vitro phase I metabolism of the synthetic cannabimimetic JWH 018. Anal. Bioanal. Chem. 398(5), 2141-2153 (2010).
- 3. Chimalakonda, K.C., Moran, C.L., Kennedy, P.D., et al. Solid-phase extraction and quantitative measurement of omega and omega-1 metabolites of JWH 018 and JWH 073 in human urine. Anal. Chem. 83(16), 6381-6388 (2011).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

# WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 06/16/2023

### **CAYMAN CHEMICAL**

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM